Evidence map›Paper›PMID 38827319›Full record

ArticleOncology research2024

Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.

Constantine N Logothetis, Nathan P Horvat, Tony Kurian, Celeste Bello, Julio Chavez, Leidy Isenalumhe, Bijal Shah, Lubomir Sokol, Hayder Saeed, Javier Pinilla and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Constantine N LogothetisDepartment of Internal Medicine, University of South Florida, Tampa, FL, 33602, USA.
Nathan P HorvatCollege of Medicine, University of South Florida Morsani, Tampa, FL, 33602, USA.
Tony KurianH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Celeste BelloH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Julio ChavezH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Leidy IsenalumheH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Bijal ShahH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Lubomir SokolH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Hayder SaeedH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Javier PinillaH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Sameh GaballaH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin's lymphomas. Only one trial has evaluated frontline BR prospectively in EMZL. This retrospective study reports outcomes among EMZL patients receiving frontline BR. Twenty-five patients were included with a median age of 69 years (40-81). Five (20.0%) patients had stage I/II disease, and 20 (80.0%) had stage III/IV disease. The median number of cycles was 6.0 (3.0-6.0). Maintenance rituximab was administered to 10 (41.7%) individuals. Overall response rate (ORR) was 100.0% (60.0% complete response, 40.0% partial response). Medians of overall survival and progression-free survival were not reached. The estimated 2-year progression-free survival was 85.2% and overall survival was 100.0%. Four (16.6%) patients had infections related to treatment; 3 (12.0%) transformed to diffuse large B-cell lymphoma; 5 (20.8%) had a relapse or progression of EMZL; and 3 (12.0%) died unrelated to BR. BR is an efficacious and well-tolerated front-line regimen for EMZL with response data consistent with existing literature.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideLymphoma, B-Cell, Marginal ZoneRituximabAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingProgression-Free SurvivalRetrospective StudiesTreatment OutcomeBendamustine HydrochlorideRituximabBendamustineExtranodal marginal zone lymphomaFront-line therapyRituximab

Identifiers

PMID38827319
PMCPMC11136690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.